LOUISVILLE, Colo. — August 4, 2026 — Leads & Copy — Biodesix, Inc. (Nasdaq: BDSX), a company specializing in diagnostic solutions, announced that its leadership team will participate in Canaccord Genuity’s 46th Annual Growth Conference. The conference is scheduled to take place from August 11-12, 2026, and will feature Biodesix executives in a fireside chat and in-person one-on-one investor meetings.
The fireside chat is scheduled for Wednesday, August 12, 2026, at 3:30 PM Eastern Time. The event will be held at the InterContinental Boston in Boston, Massachusetts.
A live webcast of the presentation will be available, along with a replay. Both can be accessed through the Investors section of the Biodesix website at Biodesix.com, under “News & Events.”
Biodesix is recognized as a leading diagnostics solutions company dedicated to enhancing clinical care and patient outcomes. The company’s diagnostic tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, are designed to aid clinical decisions, facilitating personalized care and improving results for individuals with lung disease.
In addition to its diagnostic tests, Biodesix offers Biodesix Development Services. These services provide scientific, technological, and operational support to leading biopharmaceutical, life sciences, and research institutions worldwide. This support is crucial for the development of diagnostic tests, tools, and therapeutics.
Source: Biodesix, Inc.
